CA-QVEST-GROUP
8.12.2020 20:52:10 CET | Business Wire | Press release
The Qvest Group, a world-leading systems architect and ICT integrator, today announced the acquisition of the majority of OnPrem Solution Partners LLC, a highly reputed consultancy across the media and entertainment supply chain in the USA. OnPrem’s expertise in business and technology consulting, especially its focus on the digital media supply chain, will complement and extend the Qvest Group’s portfolio and lay the foundation to gain a foothold on the US-American market.
Headquartered in Los Angeles, with additional offices in New York and Austin, OnPrem is an end-to-end solution provider that strategizes, advises, designs and develops technology solutions, leveraging their expertise in content, customers and data for media and entertainment and consumer products industries. The acquisition brings a highly experienced team of more than 250 consultants to deliver solutions in areas such as Digital Media Supply Chain, IP and Rights Management, Data and Analytics, Customer Experience Design, Salesforce and Program Management/PMO to the Qvest Group. OnPrem has built dynamic partnerships with leading technology providers and platforms such as AWS, Salesforce and Microsoft.
“OnPrem strengthens the position of the Qvest Group as a leading partner in digital media, data and cloud management and considerably enhances our capacity to provide clients with added value, scale, and world-class expertise,” said Peter Nöthen, CEO of the Qvest Group. “For Qvest, this is also the steppingstone to the largest market for broadcast & media in the world which significantly raises our international business in technology consultancy and systems integration. Moreover, joining forces with OnPrem enables us to better and directly support worldwide operating clients and it also generates the ground for the growth of our cloud management platform qibb in the US-American market.”
Frank Leal, Partner at OnPrem, agrees: “The leadership at OnPrem is excited and inspired by our new Qvest partnership. With Qvest’s focus on the media industry and quality and their international presence, there was no better fit for us. This transaction creates a worldwide entity that is a partner to CTOs, CIOs and Broadcast Engineers everywhere. Most importantly, we were able to join a leadership team with a similar philosophy on culture and talent, providing additional opportunities for our team members and creating an organization that is a home to the best consultants and engineers in the world.”
The Qvest Group, headquartered in Germany, has offices across Europe, the Middle East, APAC, and Australia. The company has been accelerating the digital transformation of its clients, offering capabilities in technology design consultancy and systems integration, software development, cloud engineering, and technical infrastructure operations.
For OnPrem, Qvest’s service offerings and global scale will help to meet its clients’ growing needs for architecture design, seamless technology integration and realizing large-scaled media infrastructure projects along the entire digital media value chain.
As part of the acquisition, the Qvest Group acquired 55 % of the shares in OnPrem. The contract was signed on December 2, 2020. The partners at OnPrem, Frank Leal, Candice Lu, Christophe Ponsart, Jon Christian, and Vanessa Fiola, along with leadership will continue to build on its long-standing, valued relationships with employees and clients.
About Qvest Group
Qvest is a world-leading systems architect, consultant and ICT integrator in the innovation-driven media industry. The company’s range of services is aligned to the opportunities emerging from an increasingly digital media value chain such as multi-platform content delivery, AI, big data analysis, multi-cloud management and IP infrastructures. Qvest Media’s clients include renowned media networks, telecommunication providers, broadcasters, companies and organizations from the industrial and public sector. Next to the headquarters in Cologne, Qvest Media operates further locations in Europe, the USA, MENA & APAC.
About OnPrem
OnPrem Solution Partners is an end-to-end solution provider that strategizes, advises, designs, develops and integrates world-class technology. Experts in Digital Media Supply Chain, IP and Rights Management, CRM, AI, Data & Analytics, PMO/Project management and custom development, OnPrem connects disparate parts of an organization to enable operational excellence. Based in Los Angeles with offices in New York and Austin Texas, OnPrem offers its expertise within the Media & Entertainment, Consumer Packaged Goods industries and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208006050/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom